PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival-Reference-Cited by-同舟云学术

PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival

Published:2015-08-19 Issue:32 Volume:6 Page:33019-33032
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Fang Wenfeng¹²,Hong Shaodong¹²,Chen Nan³,He Xiaobo³,Zhan Jianhua¹²,Qin Tao¹²,Zhou Ting¹²,Hu Zhihuang¹²,Ma Yuxiang¹²,Zhao Yuanyuan¹²,Tian Ying¹²,Yang Yunpeng¹²,Xue Cong¹²,Tang Yanna³,Huang Yan¹²,Zhao Hongyun¹²,Zhang Li¹²

Affiliation:

1. State Key laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China

2. Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

3. Department of Oncology, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary Pulmonary Lymphoepithelioma-like Carcinoma: A Case Report Utilizing Camrelizumab and Anlotinib for Prolonged Survival;Anti-Cancer Agents in Medicinal Chemistry;2024-07

2. Neoadjuvant Therapy Before Resection of Primary Pulmonary Lymphoepithelial Carcinoma;Clinical Lung Cancer;2024-06

3. Combination of chemotherapy and immunotherapy may overcome the resistance to immunotherapy alone in pulmonary lymphoepithelial carcinoma;The Kaohsiung Journal of Medical Sciences;2024-04-09

4. Single Nuclei Transcriptome Reveals Therapeutic Targets and Microenvironment in Primary Pulmonary Lymphoepithelioma‑Like Carcinoma.Single Nuclei Transcriptome Reveals Therapeutic Targets and Microenvironment in Primary Pulmonary Lymphoepithelioma‑Like Carcinoma;2024

5. Treatment options for stage III-N2 pulmonary lymphoepithelioma-like carcinoma: A retrospective cohort study;Radiotherapy and Oncology;2023-12